Elite Pharmaceuticals Inc (ELTP)

[kayak_wench]

Of course the abuse deterrent technology has some value, versus the company not having the patents or technology at all, but I don't think very much at the moment. Value by investors won't be recognized until someone shows money can be made off abuse deterrent formulations. Not many companies are excited or working on abuse deterrent drug, but some are. The research shows that the case simply hasn't been made that its worthwhile to spend more on these products. Abuse deterrent drugs have not gained traction in the past 10 years at all. If one comes to market and starts making big bucks because doctors prescribe it over lower price alternatives then Elite may return to utilizing that technology. But until then I think Nasrat will wisely stay on the side lines. Elite doesn't have the money to create a market, we need to stick to pushing our way into established billion dollar markets.

From recent journal article by NIH on the issues in the abuse deterrent opioid market (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11162618/)

ADF utilization has been hampered by patient access issues, including high prices due to lack of insurance coverage. Postmarket real-world studies demonstrate lower rates of abuse, misuse, and diversion for ADF ER opioids compared with non-ADF formulations. However, similar studies comparing abuse-related effectiveness and health care costs for ADF opioids are warranted if clinicians are expected to utilize these potentially safer opioid formulations. These studies would support further education surrounding the benefits and utilization of ADFs and manipulation potential of different ADFs.